Ovid Therapeutics Inc. (NasdaqCM: OVID)
Health Care · Biotechnology · US
$2.91
+3.19% today · +138.5% 1Y
Ovid Therapeutics Inc. (NasdaqCM: OVID) operates in the Biotechnology industry within the Health Care sector. The company is valued at $568.32M and employs 23 people.
Over the last twelve months the share price has gained 138.5%, trading between 0.89 and 3.11.
Tweenvest scores Ovid Therapeutics Inc. across four factors: quality 30/100, value 68/100, growth 100/100. Its strongest factor is growth.
OVID price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $568.32M
- Revenue (TTM)
- $1.58M
- P/E
- —
- EPS
- -0.28
- Dividend yield
- —
- Beta (5Y)
- 0.23
- 52-week high
- $3.11
- 52-week low
- $0.89
- Avg volume (3M)
- —
- Shares outstanding
- 195.30M
- Employees
- 23
- Next earnings
- —
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
- ISIN
- US6904691010
- Founded
- 2014
- Listed since
- May 5, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.